Flash Finance

Indegene LimitedINDGNCorporate

Healthcare Research, Analytics & Technology Latest results: Mar 2026 13 quarters of data
Consolidated Standalone
₹598.30
MCap ₹14,408 Cr · P/E 68.0
Indegene Limited — Stock analysis & AI research Indegene Limited — Seasonality — best & worst months Indegene Limited — Technical indicators & charts Indegene Limited — Technical setup — score, trend, support & resistance Indegene Limited — Ascending Channel pattern forming Indegene Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 Low Debt Stocks📋 Small Cap Stocks List 📈 Stocks Near 52-Week High📈 Bollinger Squeeze Stocks📈 Bullish EMA Alignment📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks ⚖️ vs Syngene International 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹368 Cr
Sales · Mar 2026
+37.8% YoY
₹103 Cr
Operating Profit · Mar 2026
+157.5% YoY
28.0%
OPM % · Mar 2026
+86.7% YoY
₹72 Cr
Net Profit · Mar 2026
+33.3% YoY
₹2.99
EPS · Mar 2026
+32.3% YoY

📝 Indegene Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Indegene Limited reported revenue of ₹368 crore for the quarter ended March 2026 (Q4 FY26), up 37.8% from ₹267 crore in the same quarter last year, and up 26.9% sequentially over the December 2025 quarter.

Net profit rose 33.3% year-on-year to ₹72 crore, from ₹54 crore. Earnings per share (EPS) came in at ₹2.99.

Operating profit stood at ₹103 crore — an operating margin (OPM) of 28.0%, compared with 15.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Indegene Limited posted revenue of ₹1,220 crore, a growth of 11.5% over FY25, with a net profit of ₹212 crore (up 16.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,220 crore with a net profit of ₹212 crore.

Valuation snapshot

At the current price of ₹598.30, INDGN has a market capitalisation of ₹14,408 crore and a trailing P/E of about 68.0.

Within the Healthcare Research, Analytics & Technology industry, it is the largest of the 10 companies we track by market value.

Shareholding pattern

As of Mar 2026, foreign institutional investors (FIIs) 10.27%, domestic institutional investors (DIIs) 8.29%, public shareholders 81.43% of Indegene Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹14,408 Cr
Current Price ?
₹598.3
P/E ?
68.02above ind
Industry P/E ?
35.60
P/B ?
6.93
P/S ?
11.81
P/FCF ?
47.71
Enterprise Value ?
₹14,478 Cr
EV/EBITDA ?
58.38
PEG ?
3.78
Earnings Yield ?
1.5%
Dividend Yield ?
0.33%
Profitability & Returns
Sales (TTM) ?
₹1,220 Cr
OPM ?
20.3%
Profit after tax (TTM) ?
₹212 Cr
EPS (TTM) ?
₹8.80
ROCE ?
14.0%
ROE ?
10.2%
ROA ?
8.5%
Growth
Sales — latest qtr ?
₹368 Cr
PAT — latest qtr ?
₹72 Cr
YoY qtr sales growth ?
37.8%
YoY qtr profit growth ?
33.3%
Sales growth (3y) ?
7%
Sales growth (5y) ?
19%
Profit growth (3y) ?
18%
Profit growth (5y) ?
10%
Financial Health
Debt ?
₹70 Cr
Debt to Equity ?
0.03
Interest Coverage ?
24.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
N/A
Change in promoter holding ?
N/A
Pledged percentage ?
N/A
Market
Return 3 months ?
17.1%
Return 6 months ?
22.8%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 256252260260272259282287267256307290368 +37.8% +26.9%
Operating Profit 443843374640465240377138103 +157.5% +173.2%
Other Income 91261223142222353218236 -82.9% -73.5%
Interest 2222222222223 +50.0% +66.7%
Depreciation 1098687667791011 +57.1% +15.8%
Profit Before Tax 42393941604561666660784995 +43.9% +93.9%
Net Profit 28302930493345505445603572 +33.3% +106.9%
EPS 1.281.331.321.332.201.361.882.092.261.882.501.452.99 +32.3% +106.2%
OPM % 17.2% 15.1% 16.5% 14.2% 16.9% 15.4% 16.5% 18.1% 15.0% 14.4% 23.0% 13.0% 28.0% +86.7% +115.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,094 Cr ₹1,220 Cr ₹1,220 Cr +11.5%
Operating Profit ₹178 Cr ₹248 Cr ₹248 Cr +39.1%
OPM % 16.29% 20.32% 20.32% +24.7%
NPM % 16.60% 17.35% 17.35% +4.5%
Other Income ₹94 Cr ₹78 Cr ₹78 Cr -16.5%
Depreciation ₹27 Cr ₹36 Cr ₹36 Cr +36.3%
Interest ₹7 Cr ₹8 Cr ₹8 Cr +18.1%
EBIT ₹152 Cr ₹212 Cr ₹212 Cr +39.6%
PBT ₹238 Cr ₹281 Cr ₹281 Cr +18.1%
Tax ₹32 Cr ₹46 Cr ₹46 Cr +43.5%
Net Profit ₹182 Cr ₹212 Cr ₹212 Cr +16.6%
EPS ₹7.59 ₹8.82 ₹8.82 +16.2%
Material Cost — — — —
Employee Cost ₹389 Cr ₹582 Cr ₹582 Cr +49.4%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 44444848 +0.0%
Reserves 7519091,8402,032 +10.4%
Borrowings 51382770 +159.3%
Other Liabilities 191228234332 +41.9%
Total Liabilities 1,0381,2202,1502,482 +15.4%
Fixed Assets 785653113 +113.2%
CWIP 00412 +200.0%
Investments 4006249751,318 +35.2%
Other Assets 5595401,1191,039 -7.1%
Total Assets 1,0381,2202,1502,482 +15.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 82176129346 +168.2%
Cash from Investing Activity -51-189-824-272 +67.0%
Cash from Financing Activity -17-16717-63 -108.8%
Net Cash Flow 14-292211 -50.0%
Free Cash Flow 66166112302 +169.6%
CFO/OP 70%134%111%159% +43.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 14513214085 -39.3%
Cash Conversion Cycle 14513214085 -39.3%
Working Capital Days 113104121261 +115.7%
ROCE % 24%18%17%14% -17.6%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
FIIs 10.04%11.30%11.48%10.27% -10.5%
DIIs 7.20%6.95%8.06%8.29% +2.9%
Public 82.75%81.74%80.44%81.43% +1.2%
No. of Shareholders 1,51,9971,51,8091,47,1821,42,119 -3.4%

⚖️ Peer comparison

Industry: Healthcare Research, Analytics & Technology · 10 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 INDGN Indegene ₹597.05 14,377 35.8 3,812 401 16.7% 10.5% 23.6% -1.5% 39.7% -0.2%
2 SUVEN Suven Life ₹286.25 8,088 — 9 -353 -3955.0% -3815.2% 6.9% -71.9% 114.3% -148.5%
3 VIMTALABS Vimta Labs ₹637.20 2,847 35.7 419 80 34.4% 19.1% 18.0% 19.5% 11.3% 10.7%
4 FABTECH Fabtech Technologies ₹145.66 647 44.8 364 14 2.4% 4.0% — — 10.3% 168.7%
5 526853 Bilcare Ltd-$ ₹61.25 215 — 773 -6 9.1% -0.8% -6.9% 36.7% 21.2% 253.4%
6 TAKE Take Solutions ₹12.69 186 14.6 85 13 -2.0% 15.2% — -71.0% — 216.8%
7 536565 Novelix Pharmaceuticals ₹19.88 181 13.2 147 4 3.1% 2.5% 330.7% 2218.2% 65.2% 971.7%
8 538837 Jeevan Scientific ₹50.96 178 22.6 71 5 20.5% 7.2% 31.4% 1371.4% 107.7% 127.0%
9 543309 Adeshwar Meditex ₹27.50 24 31.2 56 1 4.9% 2.2% — — -30.4% -60.4%
10 540729 Vanta Bioscience ₹51.45 15 333.1 2 0 55.8% 6.1% — — 357.6% 240.9%
❓ Frequently asked questions
What was Indegene Limited's revenue in Q4 FY26?
Indegene Limited reported revenue of ₹368 crore for the quarter ended March 2026 (Q4 FY26), up 37.8% from ₹267 crore in the same quarter last year, and up 26.9% sequentially over the December 2025 quarter.
What was Indegene Limited's net profit in Q4 FY26?
Net profit rose 33.3% year-on-year to ₹72 crore, from ₹54 crore. Earnings per share (EPS) came in at ₹2.99.
What is INDGN's market capitalisation and P/E ratio?
At the current price of ₹598.30, INDGN has a market capitalisation of ₹14,408 crore and a trailing P/E of about 68.0.
Who owns Indegene Limited? (shareholding pattern)
As of Mar 2026, foreign institutional investors (FIIs) 10.27%, domestic institutional investors (DIIs) 8.29%, public shareholders 81.43% of Indegene Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI